ING Groep NV Sells 9,009 Shares of Insulet Corporation $PODD

ING Groep NV trimmed its stake in Insulet Corporation (NASDAQ:PODD) by 52.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,291 shares of the medical instruments supplier’s stock after selling 9,009 shares during the quarter. ING Groep NV’s holdings in Insulet were worth $2,357,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Larson Financial Group LLC increased its holdings in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the last quarter. Elyxium Wealth LLC acquired a new position in shares of Insulet in the fourth quarter valued at $28,000. Fideuram Asset Management Ireland dac acquired a new position in shares of Insulet in the fourth quarter valued at $41,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Insulet in the third quarter valued at $49,000. Finally, Osterweis Capital Management Inc. acquired a new position in shares of Insulet in the second quarter valued at $51,000.

Insider Activity at Insulet

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.36% of the company’s stock.

Insulet Trading Up 5.3%

Shares of Insulet stock opened at $159.61 on Wednesday. The company has a market capitalization of $11.05 billion, a price-to-earnings ratio of 37.12, a PEG ratio of 1.19 and a beta of 1.13. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 12-month low of $140.63 and a 12-month high of $354.88. The firm’s 50-day moving average price is $173.43 and its two-hundred day moving average price is $235.68.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter in the previous year, the firm earned $1.02 EPS. Insulet’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, analysts forecast that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on PODD. Truist Financial dropped their price target on Insulet from $315.00 to $250.00 and set a “buy” rating for the company in a report on Thursday, May 7th. BTIG Research dropped their price target on Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a report on Tuesday, May 26th. Evercore dropped their price target on Insulet from $240.00 to $200.00 in a report on Thursday, May 7th. Sanford C. Bernstein dropped their price target on Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, William Blair began coverage on Insulet in a report on Wednesday, May 20th. They set an “outperform” rating for the company. Twenty-one research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $250.00.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.